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Chandrashekhar R GandhiAbstract
‘Augmenter of liver regeneration’ (ALR) (also known as hepatic stimulatory substance or hepatopoietin) was
originally found to promote growth of hepatocytes in the regenerating or injured liver. ALR is expressed
ubiquitously in all organs, and exclusively in hepatocytes in the liver. ALR, a survival factor for hepatocytes, exhibits
significant homology with ERV1 (essential for respiration and viability) protein that is essential for the survival of the
yeast, Saccharomyces cerevisiae. ALR comprises 198 to 205 amino acids (approximately 22 kDa), but is post-
translationally modified to three high molecular weight species (approximately 38 to 42 kDa) found in hepatocytes.
ALR is present in mitochondria, cytosol, endoplasmic reticulum, and nucleus. Mitochondrial ALR may be involved in
oxidative phosphorylation, but also functions as sulfhydryl oxidase and cytochrome c reductase, and causes Fe/S
maturation of proteins. ALR, secreted by hepatocytes, stimulates synthesis of TNF-α, IL-6, and nitric oxide in Kupffer
cells via a G-protein coupled receptor. While the 22 kDa rat recombinant ALR does not stimulate DNA synthesis in
hepatocytes, the short form (15 kDa) of human recombinant ALR was reported to be equipotent as or even
stronger than TGF-α or HGF as a mitogen for hepatocytes. Altered serum ALR levels in certain pathological
conditions suggest that it may be a diagnostic marker for liver injury/disease. Although ALR appears to have
multiple functions, the knowledge of its role in various organs, including the liver, is extremely inadequate, and it is
not known whether different ALR species have distinct functions. Future research should provide better
understanding of the expression and functions of this enigmatic molecule.
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Introduction
Following the discovery that the liver possesses a remark-
able ability to regenerate, pursuit to identify factors that are
involved in this phenomenon led to the discovery of many
mitogens, co-mitogens, and inhibitors. Among them was a
protein initially named hepatic stimulatory substance or
hepatopoietin and now commonly known as ‘Augmenter of
liver regeneration’ (ALR). ALR was subsequently purified,
and cloned in rat, mouse, and human. Both native and
cloned ALR augment liver regeneration following partial
hepatectomy and prevent pathology of portacaval shunt
surgery in animal models. ALR is produced and secreted
exclusively by hepatocytes in the liver and stimulates syn-
thesis of TNF-α, IL-6, and nitric oxide in Kupffer cells via a
G-protein coupled receptor. ALR may also exert actions onCorrespondence: gandhics@ upmc.edu
1VA Pittsburgh Healthcare System, Pittsburgh, PA, USA
2Thomas E. Starzl Transplantation Institute, Departments of Surgery and
Pathology, University of Pittsburgh, E-1540 BST, 200 Lothrop street,
Pittsburgh, PA 15213, USA
© 2012 Gandhi; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhepatocytes in an autocrine manner. Interestingly, intra-
cellular ALR was found to be a survival factor as its deple-
tion causes rapid mitochondrial dysfunction and apoptotic/
necrotic death of hepatocytes. In this regard, ALR exhibits
significant homology with ERV1 protein (essential for res-
piration and viability found in the yeast, Saccharomyces
cerevisiae). Thus it is not a surprise that ALR is expressed
ubiquitously in all organs, and may have tissue-specific
functions. Furthermore, post-translational modification of
the 22 kDa native ALR protein to three high molecular
weight species (38 to 42 kDa), and presence of ALR
in mitochondria, cytosol, endoplasmic reticulum, and
nucleus indicate that ALR may play an important
role in various physiological functions in a cell. Cur-
rent evidence indicates that ALR may be involved in
mitochondrial oxidative phosphorylation, reduction of
cytochrome c, and in regulation of the activities of cer-
tain proteins by its sulfhydryl oxidase activity as well
as by inducing Fe/S maturation of proteins. Thus,
although ALR appears to have multiple functions, the
knowledge of its roles in various organs, even in thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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current status of ALR research is reviewed. The intent of
this summary is to stimulate further research to unravel
the many facets of the important functions of this enig-
matic protein in physiology and pathology.
History of augmenter of liver regeneration
Liver regeneration is a fascinating phenomenon that
occurs following hepatocellular death induced by toxins,
viral infection, physical injury due to trauma or elective
resection for focal disease, and following transplantation.
The ability of the liver to regenerate is known since the
myth of Prometheus whose liver, fed to an eagle persis-
tently as a punishment for stealing fire from Zeus and
giving it to mortals, regenerated in perpetuity. The scien-
tific proof that the liver indeed possesses regenerative abi-
lity was provided by Higgins and Anderson [1] when they
demonstrated restoration of the liver mass following par-
tial hepatectomy in rats. Subsequent research led to the
discovery of several endogenously and exogenously pro-
duced growth promoters (for example, HGF, TGF-α, epi-
dermal growth factor [EGF], platelet-derived growth
factor [PDGF]), co-mitogens/priming agents (for example,
insulin, insulin-like growth factor [IGF], IL-6, TNF-α),
growth inhibitors (such as TGF-β, activins), intrinsic mo-
lecular mechanisms, and signaling pathways that partici-
pate in hepatocyte proliferation following partial resection
or death of hepatocytes due to physical, chemical or bio-
logical injury For review, see [2-5].
Early attempts to identify hepatocyte mitogens led to
the discovery that factors present in the soluble fractions
of regenerating liver or in the serum of partially hepatec-
tomized rats stimulated liver regeneration in vivo and
DNA synthesis in hepatocytes in vitro [6-9]. In 1975,
Labreque and Pesch [10] identified a protein in weanling
and regenerating rat livers that stimulated liver regene-
ration, and named it ‘hepatocyte stimulatory substance
(HSS)’. Interestingly, protein isolated simultaneously from
the normal adult rat liver exhibited inhibitory activity [10].
Similar hepatocyte stimulatory activity was also identified
in the regenerating livers of dogs [11,12], pigs [13], and
rabbits [14]. Purification attempts demonstrated that the
protein with HSS activity separated on SDS-PAGE as a
major (12,400 Da) and a minor (17,500 Da) band [15].
Subsequently, Francavilla and colleagues purified a similar
protein with molecular mass of approximately 30 kDa
from weanling rat livers, and named it ‘Augmenter of Liver
Regeneration (ALR)’ [16,17]. ALR promoted liver
regeneration following partial hepatectomy, ameliorated
galactosamine-induced liver injury, and prevented liver
pathology caused by portacaval shunt surgery in various
animal models, but did not stimulate DNA synthesis in
isolated hepatocytes reviewed in [18]. Subsequently, the
ALR protein was sequenced, and its gene cloned in rat,mouse, and human [19,20]. The ALR gene encoded a 22
kDa protein, which exhibited activity similar to the protein
extracted from hyperplastic liver in augmenting liver re-
generation following partial hepatectomy in rats and in
preventing portacaval shunt-induced liver atrophy in dogs
[19,20]. The cloned recombinant rat ALR protein (rrALR),
consistent with the earlier findings with native rat ALR
[18], did not stimulate DNA synthesis in cultured rat
hepatocytes [21,22].
ALR is homologous to yeast protein ERV1
The nucleotide and amino acid sequences of the rat and
mouse ALR (198 amino acids) are 96% and 90% homolo-
gous, respectively [20]. The human ALR (205 amino acids)
is about 90% homologous to the rodent ALR [20,23]. The
mammalian ALR exhibits significant (about 40%) hom-
ology with a protein expressed in the yeast Saccharomyces
cerevisiae (S. cerevisiae) named Essential for Respiration
and Viability 1 (ERV1) (Figure 1) [19,20,24]. Thus, ALR is
also known as growth factor ERV1 homolog of S. cerevi-
siae (GFER). Interestingly, both ERV1 [24] and ALR [19]
were initially demonstrated to be relatively small proteins
with mw of approximately14 kDa and 15 kDa, respect-
ively, and lacked typical leader sequence near the amino
terminus for import into mitochondria (Figure 1, red let-
ters). However, further investigation demonstrated that
both proteins have additional amino-terminal sequences
with mitochondrial import sequence and molecular size of
approximately 22 kDa (Figure 1) [20,25]. The 125-amino
acid and 198- or 205-amino acid forms of ALR are known
as ‘short’ and ‘long’ ALR, respectively. A protein identical
to human homologue of ERV1 with molecular weight of
about 15 kDa was cloned from human fetal liver; this pro-
tein named ‘hepatopoietin (HPO)’ exhibits 87% homology
with rat ALR [26,27], and seems to be the short form of
human ALR.
Subsequent work identified another gene ERV2 in the
yeast, with 30% homology to ERV1 at the carboxy ter-
minal [28,29]. This protein is found in microsomes
where it functions as a sulfhydryl oxidase [28]. While
ERV1 has been shown to exist as a monomer as well as
a dimer stabilized by the amino-terminal C30 and C33
[29,30], ERV2 lacks the cysteine residues required for
dimerization. It is postulated that dimerization of ERV1
may be important for its function in physiology [29,30].
Table 1 summarizes the steps in discovery of ERV1,
ERV2, and ALR genes and proteins.
Western blot analysis showed that a 22 kDa- and some
higher molecular weight (38 to 40 kDa) proteins react
with the antiserum raised against amino terminal pep-
tide segment of the rat ALR [20]. Subsequently, western
blot analysis of proteins extracted from the liver or
hepatocytes under non-reducing condition demonstrated
recognition of three distinct bands, with molecular
Figure 1 Amino acid sequence of yeast ERV1 and mouse ALR. Homology between the yeast and mouse proteins is shown by boxed amino
acids. Red letters show amino acid sequences of the proteins identified originally [19,24] with no mitochondrial targeting sequence. These
proteins, however, were found to be functionally active in augmenting liver regeneration (ALR) and maintaining cell viability (ERV1). Black letters
added to the original sequences show the physiologically produced proteins that can be imported into mitochondria.
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raised against rrALR [21]. Human ALR was also found
to separate into similar (38 to 42 kDa) protein species by
western blot analysis [31]. Under reducing conditions,
however, ALR separates as one single band with molecular
weight of about 22 kDa (Figure 2A). This suggests that the
native ALR is post-translationally modified, either via gly-
cosylation or dimerization. Indeed, several O-glycosylation
sites, but no N-glycosylation site, are found in the ALR
molecule. Although crystallography studies using ‘short’
and ‘long’ ALR have demonstrated that the proteins can
form homo-dimers [32-35], whether and how these modi-
fications as well as post-translational alterations determine
the functions of ALR in physiology and pathology remain
to be determined.
Location of ALR
ALR mRNA is expressed in heart, brain, spleen, lung,
skeletal muscle, kidney, liver, and testis of rat and mouse,
with maximal expression in the testes followed by the
liver [19,20]. ALR is present uniformly in all regions of
the liver, exclusively in hepatocytes [21]. ALR and ERV1Table 1 Both ERV1 and ALR were initially reported to be enco
125 amino acids, respectively
Protein Species Gene size Chromosomal Am
Name Location Mo
ERV1 S. Cerevisiae 1.2 kb VII 117
ERV1 S. Cerevisiae 1.2 kb VII 189
ERV2 S. Cerevisiae 1.2 kb XVI 196
ALR Rat 1.2 kb 10 125
ALR Rat ND ND 198
ALR Mouse 6.7 kb 17 198
ALR Human ND 16 205
Subsequent investigation demonstrated that these proteins are larger in size with a
(ERV2 located in microsomes), homologous to ERV1, was later discovered. ALR is pr
chromosome 16 in polycystic kidney disease 1 (PKD1) region [20,23]. The functions
functions of these proteins are described in the text in relevant sections. HR, hepatare present in the intermembrane space of mitochondria
[25,29,36]. ALR is also located in the cytosol and nucleus
[21,37,38], and ERV2 in endoplasmic reticulum [28,39].
Interestingly, unlike ERV1 that is exclusively an intra-
cellular protein [30,40,41], ALR is secreted constitutively
by hepatocytes and is present in serum [21]. Further-
more, while ALR is expressed abundantly in hepatocytes
[21], the expression of ERV1 in the yeast is very low
[42]. Thus the structural differences and distinct loca-
tions could be related to distinct functions of ALR,
ERV1, and ERV2 proteins.
ALR is also found in all regions of the brain, co-
localized with GFAP in neurons, and is specifically
present in the nucleus and external envelope of mito-
chondria. Western blot analysis demonstrated two
dimers, which under reducing condition migrated as
two bands with MW of 21 and 23 kDa [42]. Low
level mRNA expression of human ALR homologue
was also reported in renal adenocarcinoma, cystic
renal tubular epithelium, and brain [23]. Specific cel-
lular/subcellular localization of ALR in non-hepaticded by a 1.2 kb gene with protein products of 117 and
ino acids/ Mito. Leader Function Ref.
lecular weight Sequence
/~14 kDa No OxPhos/growth 24
/~22 kDa Yes OxPhos/growth 25
/~22 kDa No Sulfhydryl oxidase 28, 29
/~15,081 No HR/Anti-atrophy 19
/~22 kDa Yes HR/Anti-atrophy 19, 20
/~22 kDa Yes HR/Anti-atrophy 20
/~22 kDa Yes HR/Anti-atrophy 20, 23
mino-terminal mitochondrial targeting sequence. Another yeast protein
esent as a single gene copy located on mouse chromosome 17 or human
indicated for ALR and ERV proteins are the ones discovered initially. Other
ic regeneration; ND, not determined; OxPhos, oxidative phosphorylation.
Figure 2 Western blot showing native (A) and recombinant rat (rr) ALR (B). (A) Proteins extracted from the rat liver were separated under
non-reducing (control- CT) or reducing (25 mM dithiothreitol: DTT) conditions on a SDS-PAGE. The separated proteins were transferred to
Immobilon-P membrane (Millipore, Bedford, MA, USA), and ALR was detected with anti-rrALR Ab and ECL kit (Amersham, UK) [21]. (B) The rrALR
was subjected to SDS-PAGE under nonreducing (CT) or reducing (DTT or 5% 2-mercaptoethanol: 2-ME). While all of the high molecular weight
ALR species (38 to 42 kDa) migrate as a single 22-kDa protein under reducing condition (A), rr-ALR migrates as a single 22-kDa protein both
under reducing and non-reducing conditions.
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be determined.Functions of ALR
Survival and regeneration of hepatocytes
Early experiments showed that the crude extract of re-
generating or hyperplastic liver, but not the unmodified
adult liver, contains ALR-like activity that augmented
partial hepatectomy-induced liver regeneration and pre-
vented portacaval shunt-induced hepatic atrophy [10,11].
Based on these observations, it was proposed that ALR
is absent from the normal adult liver. However, expre-
ssion of ALR mRNA and protein in various tissues, in-
cluding the liver, of normal rat [19,20], and presence of
equivalent amounts of ALR (mRNA and protein) in rep-
licating and quiescent hepatocytes, in vivo, [21] argued
for its function in physiology.
The indication that ALR might be a protein of critical
physiological importance was provided by the finding
that ALR’s yeast ortholog ERV1 is essential for the bio-
genesis of mitochondria, normal mitochondrial morpho-
logy, and stable maintenance of mitochondria in S.
cerevisiae [24,25,40]. The mitochondrial function of ALR
and ERV1 is apparent from their presence in the inter-
membrane space of the organelle [41]. Disruption of the
ERV1 gene or null mutation in the haploid strain led to
temperature-conditional mutation resulting in altera-
tions of the mitochondrial inner membrane, complete
loss of mitochondrial genome, arrest in cell-division
cycle, and death of the yeast after a few replication
cycles [24,40,42]. It was suggested that high in vivo
stability of the ERV1 mRNA and protein could be a
reason for delayed death of the yeast with disruptedERV1 gene, despite the original low level of ERV1 ex-
pression [24].
In contrast to a lag period of a few days before the
death of S. cerevisiae with mutated ERV1 gene, inhi-
bition of ALR synthesis with ALR-mRNA antisense
oligonucleotide (ALR-AS) caused rapid (within hours)
apoptotic/necrotic death of hepatocytes [43]. The
accelerated death occurred even though significant
level of residual ALR was still present in these hepa-
tocytes. Examination of the subcellular fractions revealed
strong depletion of mitochondrial ALR followed by ATP
depletion in ALR-AS-transfected cells [43]. These results
indicate the possibility of highly dynamic movement of
ALR in and out of mitochondria. It is plausible that the ar-
rest of ALR synthesis prevents its translocation to replace
the protein that moves out of the mitochondria, thus
causing its deficiency and consequent mitochondrial
dysfunction. Further research is required for detailed
characterization of the dynamic nature of ALR in re-
lation to the mitochondrial and extramitochondrial
localization and functions.ALR and ERV1 are functionally interchangeable
The mitochondrial presence of ALR and ERV1, necessary
for the survival of hepatocytes and S. cerevisiae, respect-
ively, led to the question whether these homologous pro-
teins are functionally interchangeable. Both the 15 kDa
(short) and 22 kDa (long) cloned ALR proteins were found
to prevent portacaval shunt-induced liver atrophy in dogs
[19,20] suggesting that the antiatrophic/regenerative acti-
vity resides in the carboxy terminal sequence of the pro-
tein. This notion was confirmed by the finding that short
form of both yeast ERV1 [24] as well as human ALR [23]
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quence rescued S. cerevisiae with mutated ERV1 gene
from death. In addition to the absolute necessity of their
carboxy terminal sequences in preventing cellular atrophy
or loss of viability, these observations provided the proof
that ALR and ERV1 proteins have structural and func-
tional similarity. Indeed, growth arrest and death of S.
cerevisiae due to deletion of carboxy terminal sequence
from ERV1 could be restored by substitution with ALR’s
carboxy terminal sequence [23,44]. In contrast, the amino
terminal sequences, necessary for the translocation of
ALR or ERV1 proteins to mitochondria, are not inter-
changeable. The independence from mitochondrial DNA
and hence oxidative phosphorylation was proposed to be
the reason why the yeast lacking mitochondrial targeting
ALR/ERV1 sequence maintains viability [24,40]. However,
rigorous examination of the precise roles of mitochondrial
and extramitochondrial ALR/ERV1 in maintaining cell
viability is required.
Extracellular effects of ALR
Effects on hepatocytes
As mentioned above, the 22 kDa rrALR does not stimu-
late DNA synthesis in rat hepatocytes [21,22]. Further-
more, radioligand binding or cross-linking studies failed
to demonstrate receptor for ALR on rat hepatocytes [21].
On the other hand, using radiolabeled short (15 kDa) re-
combinant human ALR (rhALR), Wang et al. [27]
reported presence of high affinity ALR receptor in
human and rat hepatocytes. Interestingly, on a molar
basis, hepatocyte DNA synthesis stimulated by rhALR
was much stronger than that by the powerful hepatocyte
mitogens EGF and TGF-α [27]. The effects of rhALR and
the most potent hepatocyte mitogen HGF on the DNA
synthesis in human hepatocytes were also found to be
comparable [45]. Why the physiological 22 kDa rat ALR
protein fails to induce DNA synthesis in isolated hepato-
cytes, while the short human ALR is equipotent or even
stronger than EGF, TGF-α, or HGF remains a topic of
further investigation. One possibility is that the short
rhALR may instigate intracellular signaling coupled to
cell proliferation similar to these mitogens (that is, EGF,
TGF-α, or HGF). In this regard, the short rhALR was
reported to stimulate tyrosine-phosphorylation of the
EGF receptor, and subsequent activation of mitogen-
activated protein kinase in human hepatoma HepG2 cell
line [46]. Since EGF receptor can bind several mitogens
including some G-protein-coupled or other unidentified
receptor agonists [47,48], it was proposed that the short
rhALR may act in a similar manner on the EGF receptor
[46]. However, an EGF receptor-independent and ERK1/
2-MAPK-dependent pathway of human hepatocyte pro-
liferation by rhALR has also been reported [49].The short rhALR stimulates NFκB activation [50] and
polyamine synthesis [45] in human hepatocytes. In vitro,
polyamines were found to play an important role in
growth factor induced DNA synthesis in cultured rat
hepatocytes [51,52]. In vivo, polyamines are required for
hepatic regeneration [53,54], and to improve the survival
rate of rats after liver transplantation [55]. HGF and
EGF also increase the levels of a polyamine, putrescine,
during hepatocyte regeneration in vivo and DNA synthe-
sis in vitro [56]. Thus, ALR may promote liver regene-
ration by elevating polyamine levels. In fact, rhALR was
found to increase expression of c-Myc, and activities of
ornithine decarboxylase and S-adenosylmethionine de-
carboxylase, which are all involved in polyamine synthe-
sis [45]. Several groups have shown that factors such as
HGF, EGF, TNF-α, IL-6, and IL-1, which activate NFκB
and/or c-Myc signaling pathways, and promote liver re-
generation directly or by acting as priming agents [2], in-
hibit cytochrome p-450 enzymes [57-67]. Upon testing
whether ALR may exert similar effect, it was found that
rhALR caused down-regulation of cytochrome P450
enzymes in human hepatocytes suggesting that this may
be another mechanism of ALR’s role in liver regene-
ration [50]. Together, these findings lead to the postulate
that ALR may support cell proliferation by influencing
NFκB, c-Myc, polyamines, and cytochrome P-450. But
the relevance of the above-described in vitro actions of
ALR on hepatocytes to its role in their replication
in vivo is ambiguous. Since ALR is released from the
liver soon after partial hepatectomy in rats (21) and exo-
genously administered recombinant rat ALR augments
liver regeneration in this model (22), it will be critical to
investigate whether the proliferative response occurs by
ALR’s direct action on hepatocytes and/or via mediators
released from the non-parenchymal cells. Obviously, the
attendant gene and protein expression pattern related to
liver regeneration in the context of changes in hepatic
and circulating ALR, and their relationship to other
mitogens/co-mitogens and growth inhibitors will be the
areas that should be addressed rigorously.
Effects on Kupffer cells and natural killer cells
Another important mechanism of the role of ALR in un-
abated liver regeneration might be its ability to prevent
hepatocyte injury by affecting cells of the immune system,
infiltrating inflammatory cells and resident macrophages.
Earlier work demonstrated that ALR inhibits the lytic ac-
tivity of hepatic natural killer (NK) cells [68]. While hepa-
tocytes in the normal liver are resistant to the injurious
effect of NK cells, those in the regenerating liver are highly
sensitive [69]. Thus, it is critical that NK cells are rendered
ineffective in causing injury to hepatocytes during liver re-
generation. Indeed, NK cells isolated from the regenerating
livers are unable to cause lysis of YAC-1 tumor cells [69].
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negatively with peripheral blood-derived NK cell activity in
a clinical study [70]. Interestingly, the inhibitory effect of
ALR on NK cells was similar to that of HGF and IGF-1
[68]. Therefore, considering the elevated levels of HGF and
IGF-1 [2-5] following partial hepatectomy, the precise con-
tribution of ALR to liver regeneration via inhibition of NK
cells needs further examination.
Immediate release of ALR from the rat liver follow-
ing partial hepatectomy [21] indicated that the released
ALR may stimulate non-parenchymal cells to produce
mediators of hepatic regeneration. This postulate was
supported by the observation that Kupffer cells release
TNF-α and IL-6, and NO by increasing the expression
of inducible NO synthase (iNOS) upon stimulation with
rrALR [22]. These effects of ALR on Kupffer cells were
mediated via a cholera toxin-sensitive G-protein-
coupled high affinity receptor [22]. ALR-induced syn-
thesis of TNF-α, IL-6, and NO was much more modest
compared to that stimulated by endotoxin (lipopolysac-
charide (LPS)) (Figure 3). While the medium condi-
tioned by Kupffer cells inhibited hepatocyte DNA
synthesis, which was augmented when the medium was
conditioned in the presence LPS (Figure 3), ALR’s pres-
ence in the medium during conditioning by Kupffer
cells reversed the inhibitory effect [22] (Figure 3). These
observations suggest that ALR prevents or inhibits the
release of hepatocyte inhibitors by Kupffer cells, while
LPS augments this process. In vivo, it is likely that ALR
promotes liver regeneration after partial hepatectomy
[18,22] by stimulating the release of priming agents
(TNF-α, IL-6, and NO) while inhibiting the release of
anti-mitogenic agents by Kupffer cells. It can be postu-
lated that exogenously administered ALR provides
beneficial effect reported in experimental fulminant
hepatic failure [71] and cirrhosis [72] via mechanisms
involving its actions on non-parenchymal cells or even
on hepatocytes. This suggestion is supported by the ob-
servation that short rhALR protects human primary hepa-
tocytes and a human hepatocyte tumor cell line (HepG2)
from apoptosis induced by ethanol, TRAIL, TGF-β, and
actinomycin D [73]. These effects appear to be liver spe-
cific as the short rhALR failed to elicit similar response on
cell lines derived from other organs [73]. In contrast, the
short rrALR was found to protect neuronal cell line SH-
SY6Y from H2O2-induced death [74].
Enzymatic activities associated with ERV1/ALR
Protein sulfhydryl oxidase
Coppock et al. [75] identified the presence of ALR/
ERV1-homologous motif in the amino terminal portion
of quiescin (QSOX) Q6 protein that belongs to a family
of quiescin-sulfhydryl oxidases. Thioredoxin is another
protein motif at the carboxy terminal portion of QSOX.The human QSOX (quiescin Q6) gene is located on
chromosome 1q25.2, and has 12 exons comprising more
than 41,000 bp, and is highly transcribed in fibroblasts
during their quiescence [75]). Several proteins and pep-
tides, but not monothiols such as glutathione, are sub-
strates for QSOX; QSOX has a widespread presence in
endoplasmic reticulum and golgi of eukaryotes, and it is
also secreted by the cells [76-79]. However, S. cerevisiae
does not express QSOX. These observations suggested
that ALR/ERV1 may also function as sulfhydryl oxidase.
Indeed, ERV1 and ERV2 [29,30,39,40,80] as well as puri-
fied ALR [81] were found to contain FAD-linked sulfhy-
dryl oxidase activity. Crystal structures of these proteins
revealed a helix-rich fold in the carboxy terminus contain-
ing the core sulfhydryl oxidase activity with a FAD-
binding site and a conserved proximal CxxC motif
[33,40,82]. Thus both short and long ALR are able to per-
form this function. Mutation of either of two cysteine resi-
dues, that are located adjacent to the FAD, results in
inactivation of ALR’s sulfhydryl oxidase activity [33]. How-
ever, ALR and ERV1 are relatively weak sulfhydryl oxidases
on their own [29,30,40,81,82]. Perhaps ALR and ERV1
function as specialist sulfhydryl oxidase for specific cellular
substrates. It has been proposed that ALR might introduce
disulfides found in proteins located in the mitochondrial
intermembrane space, including thionein [83-85], TIM10
[85], TIM13 [86], and superoxide dismutase [87]. A func-
tional aspect of ALR-associated sulfhydryl oxidase activity
was recently reported in hepatic organogenesis in zebra
fish. Using morpholino antisense oligonucleotide tech-
nique, Li et al. [88] showed that ALR-antisense suppressed
liver outgrowth in zebra fish, and this could be rescued by
ALR overexpression, but only partly when mutant ALR
lacking sulfhydryl oxidase activity was used.Cytochrome c reductase
Allen et al. [89] reported an important role of ERV1 in the
biogenesis of small proteins imported via the Mia40-
dependent pathway in the mitochondrial intermembrane
space. ERV1 [89] and ALR [34] can also act as reductant
for cytochrome c that is imported via Mia40-independent
pathway [90,91]. Functional link of the Mia40-dependent
pathway to the distinct import pathway of cytochrome c
may thus create a route for the transfer of electrons from
the incoming precursor to cytochrome c as an acceptor.
The abundance of cytochrome c in mitochondrial inter-
membrane space argues for its function as potential oxidant
for ALR in vivo [34]. Such oxidation of ALR coupled to the
respiratory chain can provide a mechanism for prevention
or reduced generation of H2O2. Based on these observa-
tions, it is postulated that interactions between ALR/ERV1
(oxidation) and cytochrome c (reduction) could be critical
in regulating cell viability as shown by inability of the yeast
Figure 3 Effect of ALR and LPS on Kupffer cells and hepatocytes. (A) Kupffer cells (KC) were incubated with carrier (PBS), 50 nM rrALR or 100
ng/ml LPS for 24 h. The medium (KC to HC) was transferred to hepatocytes (HC). Control hepatocytes were incubated with 50 nM ALR or 100
ng/ml LPS. At 24 h, DNA synthesis ([3H]thymidine) incorporation assay was performed. While KC-conditioned medium inhibited DNA synthesis in
HC, the effect was reversed or augmented when KC were conditioned with ALR or LPS, respectively. ALR or LPS, on their own, did not affect HC
DNA synthesis, while 5 nM TGF-α exerts robust effect. (B, C) Kupffer cells were incubated in the presence of 100 ng/ml LPS or 50 nM rrALR for 24
h. The medium was aspirated and TNF-α (B) or nitric oxide product NO2 (C) were measured. *P< 0.05 vs. vehicle; **P< 0.01 vs. vehicle or 0.05 vs.
ALR; ***P< 0.001 vs. vehicle or ALR (see [22] for details of the procedures).
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Fe/S maturation of proteins
Another function associated with the ALR molecule is
its ability to induce Fe/S maturation of cellular proteins.
The entire ERV1/ALR sequence, including the poorly
conserved amino terminus, is required for ALR/ERV1 to
catalyze Fe/S assembly of cytosolic but not mitochon-
drial proteins [41]. Replacement of the amino terminus
(1 to 81) of mammalian ALR (205 aa) with 1 to 93
amino acid amino terminus sequence of yeast ERV1
enables the fusion protein to translocate into yeast mito-
chondria and function as Fe/S maturation enzyme [41].
This effect of ALR may not just be limited to hepato-
cytes. In fact, ALR has also been shown to accumulate
in mitochondria of spermatogonia and spermatocytes,
where it is suggested to play a role in assembly of Fe/Sin mitochondrial membrane proteins leading to complex
mitochondrial changes occurring during spermatogen-
esis [36]. However, it should be noted that the enzymatic
activity of ERV1 to catalyze Fe/S assembly of cytosolic
protein is relatively weak [30,37]. Additional research
should shed light on whether ALR can also cause Fe/S
maturation of mitochondrial proteins, particularly the
proteins of respiratory chain complexes, given its puta-
tive role in oxidative phosphorylation.
ALR and pathology
Considering the abundance of ALR in the liver and its
secretory nature, researchers have examined changes in
circulating and tissue levels of ALR in certain pathological
conditions. Tanigawa et al. [70] found significantly
increased serum ALR levels in patients with acute and ful-
minant hepatitis; ALR was modestly increased in chronic
hepatitis and liver cirrhosis. These data and immediate
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omy [21] suggest that alterations in serum ALR levels
could provide an indication of hepatocyte stress or injury.
In this regard, we have found that LPS increases ALR re-
lease from cultured hepatocytes and circulating ALR levels
increase in rats during endotoxemia (unpublished work).
Hepatic ALR increases rapidly but transiently following
portacaval shunt in rats, accompanied by increases in HGF,
TGF-α, and TGF-β [92]. Despite the increases in protein
levels of these growth factors (ALR, HGF, and TGF-α), the
liver undergoes atrophy. However, exogenously adminis-
tered ALR, HGF, or TGF-α prevent the pathological
changes of portacaval shunt [18]. These results indicate that
the levels endogenously produced pro-mitogenic or anti-
apoptotic factors are not sufficient to ameliorate patho-
logical development or their actions are suppressed by con-
comitantly produced anti-mitogenic/pro-apoptotic factors
such as TGF-β.
Increased mRNA and protein expression of ALR was
observed in liver from patients with cirrhosis, and hepato-
cellular and cholangiocellular carcinoma [31]. Predomin-
ant expression of ALR was found in hepatocytes and
cholangiocytes of normal, cirrhotic, or cancerous liver tis-
sue [31]. It will be of interest to find out whether elevated
ALR in cancerous or regenerating cirrhotic hepatocytes is
a causal or consequence of the disease. Whether excessive
expression of ALR in hepatocytes, that already contain
this protein in abundance, drives them to become neo-
plastic may be addressed by generating mice over-
expressing liver-specific ALR.
An area of investigation that needs to be explored is the
pathological developments in the liver due to mitochondrial
ALR deficiency. Given its role in oxidative phosphorylation,
mitochondrial ALR deficiency might induce oxidative stress
causing abnormal hepatocyte functions. In this regard, we
have found that mitochondrial ALR deficiency causes hep-
atocyte injury [43] and accumulation of lipids (unpublished
work). Although ALR deficiency-induced oxidative stress
may be a primary mechanism of lipid accumulation, the
possibility that mitochondrial ALR may directly affect fatty
acid metabolism should be considered. ALR deficiency
causes apoptosis/necrosis of hepatocytes, which induces in-
flammatory response. Inflammatory mediators are known
to induce activation of stellate cells and consequent fibro-
genic activity [93,94]. It is also reported that engulfment of
apoptotic hepatocytes by stellate cells can induce their acti-
vation [95]. Thus, it is tempting to speculate that genetic
deficiency of ALR may place human subjects at high risk to
develop steatohepatitis (alcoholic and non-alcoholic), a
topic of high clinical relevance.
Conclusions
ALR is an enigmatic protein whose functional character-
istics and their underlying mechanisms are not wellunderstood as yet despite the fact that the protein was dis-
covered more than 35 years ago and its gene cloned 18
years ago. Originally identified as an augmenter of liver
regeneration, and assumed to be present only in the hyper-
plastic liver, we now know that ALR is present ubiqui-
tously in multiple forms among eukaryotes, and its
presence in various subcellular organelles and extracellular
compartments suggests that it may have distinct and im-
portant physiological functions. Although physiologically
present as a 22 kDa protein, a large body of work has been
done using the short form of ALR (15 kDa) or its dimer.
Curiously, the short ALR has been shown to be equipotent
in stimulating DNA synthesis in hepatocytes as HGF and
TGF-α, while the 22 kDa protein is unable to stimulate
this reaction. This critical observation begs a question
whether the mitogenic property of short human ALR
could be exploited as a therapy necessitating liver regener-
ation in pathological conditions. Certainly, ALR plays a
critical role in maintaining viability of hepatocytes, and
whether it performs similar function in cells of other
organs remains to be determined. Although enzymatic ac-
tivities (sulfhydryl oxidase, Fe/S assembly, and cytochrome
c reductase) are associated with ALR, they are relatively
weak as compared to that of other known enzymes. It is
possible that ALR is highly selective in performing its
enzymatic function for specific proteins. Clearly, signifi-
cant further work has to be done to understand the mul-
tiple roles of this protein. Perhaps genetically engineered
mouse models (lacking or over-expressing ALR in specific
organs) will be required to reveal its functions.
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